Locations:
Primary results from the phase 3 ANDROMEDA study
Mutational pattern in MDS is not random, study finds
When to change treatment strategy
Durvalumab monotherapy appears safe and well-tolerated
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Phase I study also reveals possible resistance mechanisms to HER2 antibodies
Encouraging clinical efficacy with no rise in adverse events
Surprising outcome differs from previous results
Study finds good hematologic response and rapid action
Meet the Director of Cleveland Clinic’s new Center for Immunotherapy and Precision Immuno-Oncology
Screening assay effective across all stages, can identify tissue of origin
Advertisement
Advertisement
Search